Piramal Pharma Increases Stake in Yapan Bio to 74%, Making It a Subsidiary
Piramal Pharma Limited has increased its stake in Hyderabad-based Yapan Bio Private Limited from 33.33% to 74%, making Yapan Bio its subsidiary. The acquisition, finalized on August 18, 2026, involved purchasing 1,46,400 equity shares for approximately Rs 76 crore (7.95 million USD). Yapan Bio specializes in process development and GMP manufacturing services for vaccines and biologics. This move enhances Piramal Pharma's capabilities in biologics development and integrated large molecule CDMO services, supporting its ADCelerate platform for accelerated drug development.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 37/100.
Outlets measured: thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 18 Aug, 08:54 am. Other outlets followed.
- 1